Entity family

Browse drugs

Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.

3articles mentioning drugs

21drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: IMA203 ×

IMA203

This drug is selected. Its supporting articles are shown below.

Articles mentioning IMA203

3 articles · page 1 of 1

579 Quality of starting material result in high manufacturability and favorable product phenotype of IMA203, a PRAME-directed TCR T-cell therapy

jitc · abstract · 2025-11-04 · 7 matching annotations

97.3%

IMA203 PRAME PRAME-derived PRAME-directed advanced melanoma Immatics US, Inc.

…ing success and improve final product characteristics. Notably, IMA203 manufacturing achieved a 95% success rate at the RP2D (1-10x10 …

590 A first-in-human, phase 1 trial of IMA203 PRAME-directed TCR T-cell therapy with PRAME-encoding mRNA-4203 in previously treated, unresectable or metastatic cutaneous melanoma or synovial sarcoma

jitc · abstract · 2025-11-04 · 7 matching annotations

95.3%

IMA203 cyclophosphamide mRNA-4203 PRAME fludarabine synovial sarcoma Immatics US, Inc.SS advanced cutaneous melanoma

…ed by ORR, DOR, DCR, and PFS. Additionally, pharmacokinetics of IMA203 transgene levels in peripheral blood will be evaluated. The tri…

603 SUPRAME: a phase 3 trial evaluating IMA203 PRAME-directed TCR T-cell therapy vs investigator’s choice in previously treated advanced cutaneous melanoma

jitc · abstract · 2025-11-04 · 7 matching annotations

95.6%

IMA203 nivolumab pembrolizumab ipilimumab lifileucel relatlimab PRAME metastatic melanoma cutaneous melanoma

…2 and Flu 30 mg/m2 x 4 days, followed by a one-time infusion of IMA203 (1-10x 109 TCR T cells), and low-dose IL-2 (1 M IU QD x5 days, …